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MicroRNA expression patterns in human anterior cingulate and 
motor cortex: a study of dementia with Lewy bodies cases and 
controls
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1Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
2Department of Pathology, University of Kentucky, Lexington, KY 40536, USA
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Abstract
Overview—MicroRNAs (miRNAs) have been implicated in neurodegenerative diseases 
including Parkinson’s disease and Alzheimer’s disease (AD). Here, we evaluated the expression of 
miRNAs in anterior cingulate (AC; Brodmann area [BA] 24) and primary motor (MO; BA 4) 
cortical tissue from aged human brains in the University of Kentucky AD Center autopsy cohort, 
with a focus on dementia with Lewy bodies (DLB).
Methods—RNA was isolated from gray matter of brain samples with pathology-defined DLB, 
AD, AD+DLB, and low-pathology controls, with n=52 cases initially included (n=23 with DLB), 
all with low (<4hrs) postmortem intervals. RNA was profiled using Exiqon miRNA microarrays. 
Quantitative PCR for post-hoc replication was performed on separate cases (n=6 controls) and 
included RNA isolated from gray matter of MO, AC, primary somatosensory (BA 3), and 
dorsolateral prefrontal (BA 9) cortical regions.
Results—The miRNA expression patterns differed substantially according to anatomic location: 
of the relatively highly-expressed miRNAs, 150/481 (31%) showed expression that was different 
between AC versus MO (at p<0.05 following correction for multiple comparisons), most (79%) 
with higher expression in MO. A subset of these results were confirmed in qPCR validation 
focusing on miR-7, miR-153, miR-133b, miR-137, and miR-34a. No significant variation in 
miRNA expression was detected in association with either neuropathology or sex after correction 
for multiple comparisons.
Conclusion—A subset of miRNAs (some previously associated with α-synucleinopathy and/or 
directly targeting α-synuclein mRNA) were differentially expressed in AC and MO, which may 
help explain why these brain regions show differences in vulnerability to Lewy body pathology.
*Co-corresponding authors: Peter T. Nelson, MD, PhD, 311 Sanders-Brown Center on Aging, 800 S. Limestone Avenue, University 
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Introduction
Neurodegenerative diseases (NDs) are devastating brain disorders with an enormous impact 
on public health. Among the prevalent NDs are Alzheimer’s disease (AD) and dementia 
with Lewy bodies (DLB), and “gold-standard” diagnoses can only be made with certainty at 
autopsy (Beach et al., 2012; Nelson et al., 2009b; Nelson et al., 2010a). According to 
consensus-based recommendations, DLB pathology includes aberrant cerebral cortical 
deposits of insoluble α-synuclein/Lewy bodies (McKeith et al., 2004; McKeith et al., 2017). 
The prevalence of Lewy body pathology is 10%–30% in most series of dementia patients 
(Heidebrink, 2002; Neltner et al., 2016; Rahkonen et al., 2003; Sonnen et al., 2009; Zaccai 
et al., 2005). It is relatively challenging to study “pure” DLB cases since most persons with 
cortical Lewy body pathology also have comorbid AD pathology (Irwin et al., 2017; Nelson 
et al., 2009b; Nelson et al., 2010a; Nelson et al., 2010b). Notably, focused duplication of the 
gene (SNCA) that encodes α-synuclein is enough to produce α-synuclein/Lewy body 
pathology (Gwinn et al., 2011; Nishioka et al., 2006; Singleton et al., 2003), so, other gene 
regulatory factor(s) that cause increased α-synuclein expression could potentiate the 
pathology.
An enigmatic characteristic of NDs is that they tend to affect specific brain areas initially, 
and then progress to additional brain regions in a predictable sequence. Symptoms reflect 
the spatiotemporal progression. In DLB, Lewy bodies are observed in the anterior cingulate 
gyrus (Brodmann Area [BA] 24; AC) early in the disease (Thal et al., 2004). By contrast, the 
primary motor cortex (BA 4; MO) and primary somatosensory (BA 3) neocortical regions 
are relatively resistant to pathology (Thal et al., 2004).
Brain region-specific gene expression may contribute to the initiation and/or propagation of 
pathology in some parts of the brain, while causing other anatomically-defined brain areas to 
be less vulnerable. Testing this hypothesis requires factoring in gene regulatory phenomena 
in addition to mRNA levels, because mRNA is an imperfect proxy for protein levels, and 
transcription is only one among many different nodes of gene expression regulation in the 
human brain (Nelson and Keller, 2007). Thus, new information about factors that affect gene 
regulation post-transcriptionally may be helpful to achieve better understanding of ND 
pathogenesis.
MicroRNAs (miRNAs) are short (~22 nucleotides in length) noncoding RNAs that have 
been implicated in NDs (Liu et al., 2008; Nelson et al., 2008a). Encoded by small genes that 
can be located practically anywhere in the genome (Londin et al., 2015), miRNAs regulate 
gene expression in multiple ways – predominantly by interacting with mRNA “targets” post-
transcriptionally – and each miRNA has the potential to regulate dozens or even hundreds of 
targeted mRNAs (Kiriakidou et al., 2004; Liu et al., 2008; Wang et al., 2010). Relative to 
protein-coding genes, the human brain miRNA repertoire is smaller, with under 1000 
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moderately- or highly-expressed brain transcripts (Hebert and Nelson, 2012). However, 
individual miRNAs can be expressed at up to an order of magnitude higher transcript copies 
than highly expressed mRNAs (Hebert and Nelson, 2012). Furthermore, individual miRNAs 
have previously been implicated in AD and Lewy body pathology (Hebert and De Strooper, 
2009; Nelson et al., 2008a; Pietrzak et al., 2016; Ubhi et al., 2014; Weinberg et al., 2015).
Fundamental characteristics of any miRNA include the cells it is expressed in and the factors 
that are associated with expression variance. For this reason, miRNA expression profiling is 
an important tool for understanding miRNA biology in health and in disease states. 
Although there have been prior expression profiling studies of miRNAs in human tissues, 
many brain areas have not been assessed thoroughly to date, and there are many extant 
unanswered questions. For example, the miRNA profiles in AC and MO regions have not 
been compared with each other and the relevance of miRNAs to DLB is unknown.
To address these issues, we evaluated the expression of miRNAs in well-characterized 
human brains. We focused specifically on AC and MO tissue from aged human brains that 
had been snap-frozen in liquid nitrogen at autopsy from the University of Kentucky 
Alzheimer’s Disease Center (UK-ADC) cohort. We were interested in testing whether the 
miRNA expression patterns varied according to anatomic region, sex, and/or 
neuropathology.
Results
Human brain samples were obtained at autopsies after short post-mortem interval (PMI), 
followed by dissection of gray matter for RNA isolation and miRNA expression profiling. 
The rationale for the areas of brain chosen for miRNA analyses is depicted in Fig. 1. Some 
aspects of RNA quality are depicted in Fig. 2. Patient characteristics, including clinical and 
pathological parameters, and PMI, are shown in summary form in Table 1. Provided in 
supplemental material are the following additional data: case-by-case clinical, pathological, 
PMI, and RNA Integrity Number (RIN) data (Supplemental Table 1). Note that a total of 7 
microarrays failed QC due to RIN values <4.0. We also note that, as we have reported 
previously, “pure DLB” is relatively rare and predominantly seen in males (Nelson et al., 
2009b; Nelson et al., 2010a; Nelson et al., 2010b), whereas most cases with DLB pathology 
have concomitant AD pathology (Irwin et al., 2017). Thus, a group of cases with AD 
pathology but no Lewy bodies was used as a control cohort. The total number of tested 
subjects with DLB pathology was 23, of which 16 had substantial comorbid AD pathology.
All the miRNA expression data for each case are provided in Supplemental Tables 2 and 3. 
All of the values of miRNA expression depicted in Tables 2–5 were the result of a statistical 
approach that enabled the use of microarray data from the two rounds of evaluations, as 
described in the Methods section. A total of 481 relatively high-expressing miRNAs met the 
inclusion criterion (log-2 expression >7 in at least one data set) and were the basis of further 
analyses.
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MiRNAs differentially expressed by brain area
Even after correcting for multiple comparisons, 150 of the relatively highly-expressed 
miRNAs were detected at different levels in the MO and AC samples across all conditions 
and microarray iterations. Of these, 119 (79%) were higher expressed in MO (versus AC), 
whereas 31 (21%) were higher expressed in AC. Table 2 shows the 10 miRNAs most highly 
expressed in MO and the 10 miRNAs most highly expressed in AC in terms of the statistical 
comparison. All of the miRNAs found to be differentially expressed at a p<0.05 level after 
correction for multiple comparisons are listed in Supplemental Table 4.
MiRNAs with variation that is associated with sex and DLB pathology
After correcting for multiple comparisons to decrease likelihood of false discovery, there 
was no miRNA that showed significant differences associated with either sex or pathology-
confirmed DLB status. Shown in Table 3 are the miRNAs showing nominal association with 
sex or DLB status (p < 0.05, but not corrected for multiple comparisons).
MiR-15/107 family
Members of the miR-15/107 family of miRNAs, which share regulatory targets (Finnerty et 
al., 2010), have been linked to both AD pathology and to regulation of α-synuclein and/or 
synucleinopathy (Alderman and Yang, 2016; Gui et al., 2015; Li et al., 2014b; Liu et al., 
2014; Liu et al., 2016; Moncini et al., 2016; Nelson and Wang, 2010; Parsi et al., 2015; 
Wang et al., 2008b; Yao et al., 2010; Zhang and Cheng, 2014). Some of the miR-15/107 
miRNAs also are enriched in brain (Wang et al., 2014). Shown on Table 4 are microarray 
values of members of the miR-15/107 family: miR-15a, miR-15b, miR-16, miR-103, 
miR-107, miR-424, miR-497, miR-503, and miR-646. None of these miRNAs showed an 
association with sex and DLB pathology that was statistically significant. However, three of 
the four highest-expressing miR-15/107 family genes in the current sample – hsa-
miR-15a-5p, hsa-miR-15b-5p, and hsa-miR-16-5p – were expressed at higher levels in MO 
than AC. MiR-107 showed a trend for lower expression in association with AD pathology 
(not shown), as expected (Nelson and Wang, 2010; Wang et al., 2008b).
Other miRNAs previously implicated in α-synucleinopathy
Although we found that a subset of miRNAs were differentially expressed in the AC and the 
MO (see Table 2), these altered miRNAs were different than those previously implicated in 
α-synucleinopathy: miR-7, miR-153, miR-1643, miR-34b, miR-34c, miR-214, miR-26b, 
miR-320, miR-20, miR-128, miR-133, miR-433, miR-205, miR-224, miR-301b, and 
miR-373 (Choi et al., 2014; de Mena et al., 2010; Doxakis, 2010; Fragkouli and Doxakis, 
2014; Janeczek and Lewohl, 2013; Junn et al., 2009; Kabaria et al., 2015; Kim et al., 2013; 
Kong et al., 2015; Li et al., 2014a; Ma et al., 2013; Majidinia et al., 2016; Mouradian, 2012; 
Niu et al., 2016; Patil et al., 2015; Recasens et al., 2016; Tagliafierro et al., 2017; Wang et 
al., 2008a; Wang et al., 2015; Xie and Chen, 2016; Zhou et al., 2016). Results for these 
miRNAs are shown in Table 5. None of these miRNAs showed association with sex or 
pathology that was statistically significant. However, a subset of these – hsa-miR-133a/b-3p, 
hsa-miR-34c-5p, hsa-miR-20a-5p, hsa-miR-7-5p, hsa-miR-34b-5p, hsa-miR-153-3p, hsa-
miR-320a, hsa-miR-7-2-3p – were expressed differentially in the AC and MO regions.
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Replication (qPCR) experiment for miRNA expression variance associated with anatomical 
areas
Quantitative PCR for post-hoc replication was performed on six low-pathology control cases 
(Fig. 3). As these experiments were performed for the purpose of replication, none of these 
cases were among those used in the microarray experiments. In addition to evaluating RNA 
from MO and AC in these cases, we also analyzed RNA from primary somatosensory and 
dorsolateral frontal cortical regions. Average age of death of the six individuals was 80.5 
years, average PMI was 3.5 hrs (See summary data on the six patients in Supplemental Table 
5). Tested with TaqMan single-tube miRNA RT-qPCR were the following miRNAs: 
miR-133b, miR-137, miR-153, miR-34a, and miR-7. As was found with the microarrays, 
miR-133b and miR-34a were expressed higher in the MO than AC, while miR-7 and 
miR-137 were expressed at lower level in MO than AC. Intriguingly, and extending the 
results from the microarrays to study new brain areas, primary sensory cortex (BA 3) also 
had relatively high miR-133b and miR-34a and low miR-7 and miR-137. By contrast, frontal 
cortex (BA9) had relatively low miR-133b and miR-34a and high miR-7 and miR-137. 
Some of the specific predicted miRNA recognition sites on α-synuclein mRNA (with 
miRNAs that are expressed at relatively low levels in AC) are shown in Fig. 4. A schematic 
depiction of the overall hypotheses tested and our interpretation of the data are presented in 
Fig. 5.
Discussion
The purpose of the current study was to test whether variation in miRNA levels detected in 
human brain tissue was associated strongly with any of the following: DLB pathology; sex; 
or neuroanatomical region (AC vs MO). The hypotheses that were being tested, and our 
interpretation of the results, are depicted in Fig. 5. Of these factors, we only found evidence 
of the anatomical region being associated strongly with variation in miRNA expression: 
many miRNAs were differentially expressed in AC and MO. For example, miR-133b and 
miR-34a were expressed at relatively high levels in primary motor and somatosensory 
cortices, whereas miR-7 and miR-137 were expressed at higher levels in AC and frontal 
cortex. These data are compatible with the hypothesis that brain areas with lower 
vulnerability to Lewy body pathology express higher miR-133b and miR-34a, but lower 
levels of miR-137 and miR-7.
This study had technical and theoretical limitations. Whereas the miRNA microarray results 
were referred to as a proxy for “miRNA expression”, there are other factors, including 
miRNA stability/degradation (Sethi and Lukiw, 2009) and miRNA expression platform-
related idiosyncrasies, that influenced our results. Some of the experimental conditions that 
affected RNA stability were at least partly mitigated by the short PMI (<4hrs), and the 
samples having been snap-frozen in liquid nitrogen at autopsy. However, the presence of 
purely technical variation introduced by the profiling platform is underscored by the 
different results from the two iterations of the miRNA microarray, and we have seen even 
greater variation between different platforms previously (Nelson et al., 2008b; Wang et al., 
2008c). Microarrays, like PCR-based and “deep sequencing” methods, each have biases 
(Hebert and Nelson, 2012). For these reasons, we posit that there is no true gold-standard 
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miRNA expression profiling method and the different methods must be used to complement 
each other, as in the current study using qPCR to validate and replicate the microarray 
results. Although our study represents one of the larger miRNA microarray studies to date 
focused on human brain, we did not have a sample size appropriate for evaluating subtle, or 
context-specific, associations between tested potential dependent variables and miRNA 
expression. This problem is exacerbated because we are testing multiple parameters and also 
many different miRNAs, so that substantial statistical corrections were required to account 
for the multiple tests.
MiRNAs have been previously linked to neurodegeneration (Delay and Hebert, 2011; Hebert 
and De Strooper, 2007; Nelson et al., 2008a; Rademakers et al., 2008) and implicated in α-
synucleinopathic conditions (Asikainen et al., 2010; Kim et al., 2007; Lim et al., 2010; 
Minones-Moyano et al., 2011; Schonrock et al., 2010). This is one of the first studies 
published to date that has focused on DLB and miRNA expression (see (Hebert et al., 
2013)). To date there is no miRNA that is specifically linked to DLB as far as we know. 
Correspondingly, we did not discover a strong association between DLB pathology and any 
particular miRNA’s expression. However, the finding of region-specific miRNA pattern may 
be clinically relevant to DLB and other diseases.
Lewy body pathology apparently spreads through the brain in a manner that is predictable; 
the AC is affected in relatively early stages of DLB, whereas the MO is generally not 
affected until late stages (Dickson et al., 2009; Toledo et al., 2016). This spatiotemporal 
sequence is inferred by cross-sectional (autopsy) studies and awaits confirmation until 
suitable biomarkers can be performed in longitudinal studies of living persons. The reason(s) 
for this common pattern of disease progression are unknown.
MiRNAs have been identified as “master regulators” of gene expression (Garofalo and 
Croce, 2011; Leung and Sharp, 2006) and so, theoretically, the different expressions of 
miRNAs in AC and MO could possibly be a factor underlying the differential vulnerability 
of these brain regions to Lewy body pathology. If this were true, then, the impact of a given 
miRNA, and a given brain area, could differ dramatically according to the circumstances—
for example, whereas the MO is affected late in DLB, the same cortical region may be 
affected relatively early in persons showing clinical and pathological features associated 
with the ALS/FTLD disease spectrum (Brettschneider et al., 2013).
Prior studies of gene expression in human brains can be correlated with our results. 
Particular miRNAs have been shown to be potential regulators of α-synuclein expression in 
the brain (Choi et al., 2014; de Mena et al., 2010; Doxakis, 2010; Fragkouli and Doxakis, 
2014; Janeczek and Lewohl, 2013; Junn et al., 2009; Kabaria et al., 2015; Kim et al., 2013; 
Kong et al., 2015; Li et al., 2014a; Ma et al., 2013; Majidinia et al., 2016; Mouradian, 2012; 
Niu et al., 2016; Patil et al., 2015; Recasens et al., 2016; Tagliafierro et al., 2017; Wang et 
al., 2008a; Wang et al., 2015; Xie and Chen, 2016; Zhou et al., 2016). Among these, the 
following miRNAs were shown to be differentially expressed in MO and AC in the current 
study: hsa-miR-133a/b-3p, hsa-miR-34c-5p, hsa-miR-20a-5p, hsa-miR-7-5p, hsa-
miR-34b-5p, hsa-miR-153-3p, hsa-miR-320a, and hsa-miR-7-2-3p. Using another approach, 
Pietrzak et al assessed RNA expression in the AC from eight DLB subjects and 10 controls, 
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and then applied bioinformatics to identify potential miRNA binding sites enriched in 
mRNAs (Pietrzak et al., 2016). This method yielded a list of candidate miRNAs that may 
participate in DLB pathogenesis. Among the 10 miRNA candidates identified (Pietrzak et 
al., 2016) – miR-25, miR-124, miR-506, miR-363, miR-82, miR-26a, miR-367, miR-1297, 
miR-140, miR-936 – we only found evidence that one (miR-25) was differentially expressed 
in AC and MO areas.
We reported previously that males are approximately three times more likely than females to 
die with relatively ‘pure’ neocortical Lewy body pathology (Nelson et al., 2010b). We also 
showed that clinicians’ knowledge of this sex-linked dimorphism in Lewy body pathology 
would improve clinical diagnostic accuracy (Nelson et al., 2010b). Smaller prior studies 
showed the same trend – males have higher DLB/cortical Lewy body risk (Barker et al., 
2002; Fujishiro et al., 2008; Hishikawa et al., 2003; Kraybill et al., 2005; Weiner et al., 
1996) and also higher Parkinson’s disease risk (Shulman and Bhat, 2006; Shulman, 2007). 
MiRNA expression is one possible explanation for sex differences; sexually dimorphic and 
sex hormone-regulated miRNA expression have been described (Bannister et al., 2009; 
Bizuayehu et al., 2012; Cutting et al., 2012; Jalava et al., 2012; Murata et al., 2010; Zhou et 
al., 2011) but these phenomena were previously not studied in human brain. In the present 
study, we could not find compelling evidence for sexually dimorphic miRNA expression in 
either AC or MO regions.
In conclusion, the current study was designed to detect large effect size phenomena related 
to variation in miRNA expression in human AC and MO. We analyzed relatively high-
quality RNA derived from well characterized human brains. Using both miRNA microarrays 
and post-hoc studies with qPCR, we identified miRNAs that are differentially expressed – 
across sex and disease states – between AC and MO, and may represent part of the reason 
for the differential vulnerability of those two brain regions to brain pathology. It is hoped 
that the data we are providing with this manuscript will enable other researchers to both 
generate and test hypotheses related to the roles of brain miRNAs in health and disease.
Methods and materials
RNA isolation from a human cerebral cortex
Samples were derived from short-PMI autopsies, representing different NDs as defined 
according to pathology. All methods were in compliance with a University of Kentucky IRB 
protocol. Premortem clinical evaluations and pathological assessments were as described 
previously (Nelson et al., 2007; Schmitt et al., 2000; Wang et al., 2008c). Tissue used for 
pathologic evaluation was dissected from MO and AC (immediately adjacent to the tissues 
sampled for RNA studies), immersion-fixed in formalin and evaluated for AD- and DLB-
type pathology using conventional methods (Nelson et al., 2009a). None of these cases has 
ever been evaluated previously using a microarray or any other high-throughput profiling 
method. The inclusion criteria that were applied for this convenience sample of DLB brains: 
PMI <4hrs; no evidence of frontotemporal dementia; no cancer in the brain parenchyma; and 
no large infarctions in the brain, or microinfarcts found within 3cm of the brain tissue 
samples. For broader inclusion/exclusion criteria of this autopsy cohort, see (Schmitt et al., 
2012). Criteria of operationalizing AD was Braak NFT stage>III with Aβ plaques more than 
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“Sparse”, whereas controls had Braak NFT stages <IV and had intact cognition in their last 
clinical examination.
RNA was isolated as previously described in detail (Wang et al., 2008b; Wang et al., 2008c). 
Briefly, RNA was extracted from the gray matter of snap-frozen cerebral cortical brain 
tissue. All biochemical analyses were performed blind with respect to patient information. 
Tissue (0.5–2 gms) that had been snap-frozen in liquid nitrogen and then transferred to a 
−80° C freezer was thawed in ice-cold isotonic lysis buffer with RNAsin (Promega, 
Madison, WI; 250 U/ml) and Complete protease inhibitor pills (Roche, Basel Switzerland). 
Prior to RNA extraction (as the tissue thawed), meninges and large blood vessels were 
removed and gray matter was carefully dissected away from white matter. Trizol LS 
(Invitrogen, Carlsbad, CA) was used according to manufacturer’s instructions, except an 
additional overnight −20°C precipitation step was included during isopropanol precipitation. 
RNA quality was confirmed using A260/A280 readings and also the Agilent Bioanalyzer for 
RIN.
Microarray methods
The quality of the total RNA after rethawing was again verified by Exiqon as part of the 
quality control process, using an Agilent 2100 Bioanalyzer profile. Two different batches of 
microarrays were analyzed, the first using the 6th generation (Product #208310) Exiqon 
miRNA microarray, miRBase version 17, and second round performed with 7th generation 
(Product #208500), miRBase version 20. Briefly, 1 μg total RNA from sample and reference 
was labeled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ 
LNA Array power labeling kit (Exiqon, Denmark) following the procedure described by the 
manufacturer. The Hy3™-labeled samples and a Hy5™-labeled reference RNA samples 
(referred to hereafter as Cy3 and Cy5) were mixed pair-wise and hybridized to the 
miRCURY™ LNA array version 11.0 (Exiqon, Denmark), which contains capture probes 
targeting all miRNAs for human, mouse or rat registered in the miRBASE version 14.0 at 
the Sanger Institute. The hybridization was performed according to the miRCURY™ LNA 
array manual using a Tecan HS4800 hybridization station. After hybridization the 
microarray slides were scanned and stored in an ozone free environment (ozone level below 
2.0 ppb) in order to prevent potential bleaching of the fluorescent dyes. The miRCURY™ 
LNA array microarray slides were scanned using the Agilent G2565BA Microarray Scanner 
System (Agilent Technologies, Inc., USA) and the image analysis was carried out using the 
ImaGene 8.0 software (BioDiscovery, Inc., USA). The quantified signals were background 
corrected (Normexp with offset value 10 as described previously (Ritchie et al., 2007)) and 
normalized using the global Lowess (LOcally WEighted Scatterplot Smoothing) regression 
algorithm.
Analytic and statistical methods
We analyzed miRNAs from RNA with RIN greater than 4.0 and mean expression (log^2) 
value greater than 7.0 in at least one of the two data sets in order to avoid analyzing miRNAs 
that were not expressed or lacking in data quality in both experiments. To analyze the data, a 
mixed model was fit to each miRNA with a random effect for each individual in the study 
and fixed effects to adjust for age and Exiqon array iteration in miRNA expression. This 
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model accounts for variability in miRNA expression across individuals, as well as for 
differences in expression due to age and Exiqon array iteration. In addition, each model 
included fixed effects for DLB (for cases where DLB severity is greater than 0) vs. non-DLB 
(cases where DLB severity is 0), sex, and brain region (AC vs. MO), plus all two-way 
interactions among these variables, and an interaction among DLB, sex, and brain. Each 
interaction allows each combination of sex, brain region, and DLB status to have a different 
association with miRNA expression, rather than forcing, for instance, differences in brain 
region to be the same in males and in females. Thus, in summary, the mixed models allow 
researchers to detect effects of DLB, brain region, and sex on miRNA expression, while 
accounting for variability across individuals and differences across age and array iteration. 
After the mixed models were fit, tests were performed to look for evidence of effects of 
interest. Specifically, tests were performed comparing the average miRNA expression across 
brain regions. Multiple testing corrections were made for fixed effect tests using a 
Benjamini-Hochberg correction. Significance was noted when the adjusted p-values for the 
corresponding test were less than 0.05.
RT-qPCR validation in separate cases of a subset of miRNAs
Quantitative PCR for post-hoc replication was performed on separate cases (n=6) and 
included RNA isolated from MO, AC, primary somatosensory, and frontal cortical regions 
as described above, all from the same cases. Different cases were used in comparison to 
those above—only controls lacking substantial DLB or AD pathology were evaluated for 
these replication experiments. RNA was extracted as above and evaluated with TaqMan® 
single-tube miRNA RT-qPCR (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. An equal quantity (350 ng) of RNA was used in the TaqMan® single-tube 
assays. TaqMan® assays were designed to follow MIQE (Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments) guidelines (Bustin et al., 2009).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Rationale for selecting brain tissue for RNA extraction and miRNA profiling in the 
current study
Particular brain areas show different vulnerabilities to specific brain diseases. Whereas the 
anterior cingulate gyrus (AC; Brodmann area 24) is affected early in DLB, the primary 
motor cortex (MO; Brodmann area 4) is generally not affected until late in the disease, if at 
all.
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Figure 2. Focus on technical factors using high-quality RNA probed with state-of-the-art miRNA 
microarrays
Quality control (QC) included Agilent BioAnalyzer (electropheragram, A), and the RNA 
Integrity Number (RIN) were mostly between 6-8, with inclusion criteria of RIN >4.0. Gray 
matter dissection was performed as described previously (Nelson et al., 2008b; Nelson and 
Wang, 2010; Wang et al., 2008c; Wang et al., 2011). For added QC, we performed extra 
technical replicates of six different samples a month after the primary microarrays were run 
and these showed within-case correlations (B is a representative correlation), demonstrating 
outstanding replicability. C. Variability in microarray signals correlated poorly with RIN 
number indicating that RNA integrity (>=4) and RNA degradation had weak impact on 
miRNA expression results in our preliminary samples. Shown here are results for miR-34a 
which are representative.
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Figure 3. RT-qPCR results on a replication cohort (n=6) separate from those studied with 
miRNA microarrays, in order to compare the expression of miRNAs in primary sensorimotor 
cortex (SEN—blue bars); primary motor cortex (MO–orange); dorsolateral frontal cortex 
(FRON–gray); and anterior cingulate gyrus (AC–yellow)
A subset of miRNAs were chosen that had differential expression in MO and AC according 
to the microarray studies, and had also been implicated in Lewy body disease and/or α-
synuclein regulation. Note that miR-133b and miR-34a were expressed at higher levels in 
primary somatosensory cortex and motor cortex, whereas miR-137 and miR-7 were 
expressed at lower levels in these brain areas. However, miR-153 did not show differential 
expression in these samples. *-p<0.05; **-p<0.01 using Student’s t-test. Error bars = StDev.
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Figure 4. 
One hypothesis for why neurons in the anterior cingulate gyrus are vulnerable to α-
synuclein/Lewy body pathology is that relatively low expression of miRNAs that target the 
3′-untranslated region (3′UTR) of α-synuclein in the anterior cingulate gyrus could be 
partly responsible. The results of the current study were correlated with a miRNA web-based 
miRNA/mRNA target prediction algorithm (Betel et al., 2010; John et al., 2004) to highlight 
the potential target sites on the 3′UTR of the SNCA transcript that may be relevant to this 
hypothesis. These putative miRNA recognition elements all are “conserved miRNAs with 
good mirSVR scores” according to the website (http://www.microrna.org/microrna/faq.do).
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Figure 5. 
Schematic depiction of three separate hypotheses related to brain miRNA expression that 
could help explain differences in vulnerability to neurodegenerative diseases that are at least 
partially sex-specific and region-specific. HYPOTHESIS 1: the combination of underlying 
pathogenic mechanisms and the pathologic phenotype alter the neurochemical milieu and 
result in a condition-specific miRNA profile. The current study did not find support for this 
hypothesis with the caveat that the sample sizes were relatively small and thus statistically 
underpowered to correlate subtle variations in miRNA expression patterns with various 
pathologic and demographic parameters. HYPOTHESIS 2: there are sex-specific miRNA 
expression patterns that help to explain the differential vulnerability of males and females to 
subtypes of neurodegenerative diseases. The current study did not find evidence of robust 
sex-specific miRNA expression patterns in the sampled brain regions. HYPOTHESIS 3: 
there are neuroanatomic area-specific patterns of miRNA expression that may help cause 
those brain regions to have region-specific vulnerability to pathologic phenotypes. Since 
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there were robust differences detected in miRNA patterns across brain regions, including 
among miRNAs that are hypothesized to target disease-relevant transcripts, we interpret the 
data from the current study to be compatible with this hypothesis.
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Table 1
Summary information on cases used in the current study
For detailed information on each case, see Supplemental Table 1
Pathology-defined case categories n n, F Avg age at death PMI (Hrs Avg)
Ctrl 16 8 82.4 2.8
DLB 7 2 82.7 2.6
AD 13 8 89.8 2.5
AD+DLB 16 10 79.0 2.7
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